Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- Registration Number
- NCT02568280
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Europe. The aim of the trial is to investigate the postprandial glucose metabolism after treatment with faster-acting insulin aspart in subjects with type 1 diabetes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
- Male or female aged 18-64 years (both inclusive) at the time of signing informed consent
- Subjects diagnosed (clinically) with type 1 diabetes mellitus at least 365 days prior to the day of screening
- Body mass index 18.5-28.0 kg/m^2 (both inclusive)
Exclusion Criteria
- Smoker (defined as a subject who is smoking at least five cigarettes or the equivalent per day) who is not able or willing to refrain from smoking or use of nicotine gum or transdermal nicotine patches during the inpatient period
- Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Faster aspart Faster-acting insulin aspart - Insulin aspart insulin aspart -
- Primary Outcome Measures
Name Time Method Mean change in plasma glucose concentration From 0-1 hour after trial product administration
- Secondary Outcome Measures
Name Time Method Rate of endogenous glucose production From 0-6 hours after trial product administration Area under the serum insulin aspart concentration-time curve From 0-6 hours after trial product administration
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇦🇹Graz, Austria